Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- SNPX
- Price
- 2.15
- Stock movement up
- +0.04 (2.09%)
- Company name
- Synaptogenix Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 2.91M
- Ent value
- -7.01M
- Price/Sales
- 283.02
- Price/Book
- 0.22
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -88.89%
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -56.58%
- 3 year return
- -77.38%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-11
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
SNPX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 283.02 |
| Price to Book | 0.22 |
| EV to Sales | -682.12 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 1.36M |
| EPS (TTM) | -6.23 |
| FCF per share (TTM) | -3.04 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 10.27K |
| Gross profit (TTM) | -2.72K |
| Operating income (TTM) | -6.76M |
| Net income (TTM) | -8.22M |
| EPS (TTM) | -6.23 |
| EPS (1y forward) | -8.54 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -26.44% |
| Operating margin (TTM) | -65841.29% |
| Profit margin (TTM) | -79988.22% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 19.63M |
| Net receivables | 0.00 |
| Total current assets | 22.28M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 22.83M |
| Accounts payable | 286.35K |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 340.89K |
| Total liabilities | 9.71M |
| Shareholder's equity | 13.12M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -4.78M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -4.02M |
| Dividends paid (TTM) | 3.57M |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -62.65% |
| Return on Assets | -36.00% |
| Return on Invested Capital | -62.65% |
| Cash Return on Invested Capital | -30.62% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.19 |
| Daily high | 2.45 |
| Daily low | 2.13 |
| Daily Volume | 22K |
| All-time high | 1288.00 |
| 1y analyst estimate | 14.00 |
| Beta | 1.43 |
| EPS (TTM) | -6.23 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| SNPX | S&P500 | |
| Current price drop from All-time high | -99.83% | -14.41% |
| Highest price drop | -99.84% | -56.47% |
| Date of highest drop | 7 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -86.57% | -11.07% |
| Avg time to new high | 121 days | 12 days |
| Max time to new high | 1047 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
2.91M
Marketcap category
Small-cap
Description
Synaptogenix, Inc. operates as a clinical-stage biopharmaceutical company. It is conducting clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Its preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders, such as multiple sclerosis, stroke, and traumatic brain injury. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome. The company was incorporated in 2012 and is headquartered in New York, New York.
Employees
5
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partner